The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Open accessAbstract
UNLABELLED: Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection. However, until now, approaches to reverse HIV-1 latency in humans have yielded mixed results. Here, we report a proof-of-concept phase Ib/IIa trial where 6 aviremic HIV-1 infected adults received intravenous 5 mg/m2 romidepsin (Celgene) once weekly for 3 weeks while maintaining ART. Lymphocyte histone H3 acetylation, a cellular measure of the pharmacodynamic response to romidepsin, increased rapidly (maximum fold range: 3.7–7.7 relative to baseline) within the first hours following each romidepsin administration. Concurrently, HIV-1 transcription quantified as copies of cell-associated un-spliced HIV-1 RNA increased significantly from baseline during treatment (range of fold-increase: 2.4–5.0; p = 0.03). Plasma HIV-1 RNA increased from <20 copies/mL at baseline to readily quantifiable levels at multiple post-infusion time-points in 5 of 6 patients (range 46–103 copies/mL following the second infusion, p = 0.04). Importantly, romidepsin did not decrease the number of HIV-specific T cells or inhibit T cell cytokine production. Adverse events (all grade 1–2) were consistent with the known side effects of romidepsin. In conclusion, romidepsin safely induced HIV-1 transcription resulting in plasma HIV-1 RNA that was readily detected with standard commercial assays demonstrating that significant reversal of HIV-1 latency in vivo is possible without blunting T cell-mediated immune responses. These finding have major implications for future trials aiming to eradicate the HIV-1 reservoir. TRIAL REGISTRATION: clinicaltrials.gov NTC02092116.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., et al. (1997) · Science · doi:10.1126/science.278.5341.1295 · Cited by 3,098
Fitzgerald, M., Hayward, I. P., Thomas, A. C., Campbell, J. H., & CAMPBELL, G. R. (1995) · Cited by 2,552
Hu, Y., & Smyth, G. K. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.008 · Cited by 2,083
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
Chun, T.-W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., et al. (1997) · Nature · doi:10.1038/387183a0 · Cited by 2,050
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
Chomont, N., El-Far, M., Ancuta, P., Trautmann, L., Procopio, F. A., Yassine-Diab, B., Boucher, G., Boulassel, M.-R., Ghattas, G., Brenchley, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1972 · Cited by 1,722
Self-citationWei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
Specific HIV integration sites are linked to clonal expansion and persistence of infected cells
Maldarelli, F., Wu, X., Su, L., Simonetti, F. R., Shao, W., Hill, S., Spindler, J., Ferris, A. L., Mellors, J. W., Kearney, M. F., et al. (2014) · Science · doi:10.1126/science.1254194 · Cited by 849
The Challenge of Finding a Cure for HIV Infection
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., & Pomerantz, R. J. (2009) · Science · doi:10.1126/science.1165706 · Cited by 846
HIV-1 replication is controlled at the level of T cell activation and proviral integration.
Stevenson, M., Stanwick, T. L., Dempsey, M. P., & Lamonica, C. A. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08274.x · Cited by 800
Shan, L., Deng, K., Shroff, N. S., Durand, C. M., Rabi, S. A., Yang, H.-C., Zhang, H., Margolick, J. B., Blankson, J. N., & Siliciano, R. F. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.014 · Cited by 714
Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection
Wagner, T. A., McLaughlin, S., Garg, K., Cheung, C. Y. K., Larsen, B. B., Styrchak, S., Huang, H. C., Edlefsen, P. T., Mullins, J. I., & Frenkel, L. M. (2014) · Science · doi:10.1126/science.1256304 · Cited by 677
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys
Whitney, J. B., Hill, A. L., Sanisetty, S., Penaloza-MacMaster, P., Liu, J., Shetty, M., Parenteau, L., Cabral, C., Shields, J., Blackmore, S., et al. (2014) · Nature · doi:10.1038/nature13594 · Cited by 629
Rasmussen, T. A., Tolstrup, M., Brinkmann, C. R., Olesen, R., Erikstrup, C., Solomon, A., Winckelmann, A., Palmer, S., Dinarello, C., Buzon, M., et al. (2014) · The Lancet HIV · doi:10.1016/s2352-3018(14)70014-1 · Cited by 628
Self-citationDeeks, S. G. (2012) · Nature · doi:10.1038/487439a · Cited by 604
Palmer, S., Wiegand, A. P., Maldarelli, F., Bazmi, H., Mican, J. M., Polis, M., Dewar, R. L., Planta, A., Liu, S., Metcalf, J. A., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4531-4536.2003 · Cited by 604
Van Lint, C., Emiliani, S., Ott, M., & Verdin, E. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00449.x · Cited by 580
Histone deacetylases as regulators of inflammation and immunity
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., & Sweet, M. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.001 · Cited by 546
Pierson, T., McArthur, J., & Siliciano, R. F. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.665 · Cited by 545
Li, T., Tubiana, R., Katlama, C., Calvez, V, Mohand, H. A., & Autran, B. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10291-4 · Cited by 544
Elliott, J. H., Wightman, F., Solomon, A., Ghneim, K., Ahlers, J., Cameron, M. J., Smith, M. Z., Spelman, T., McMahon, J., Velayudham, P., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004473 · Cited by 504
Self-citationBroad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
Deng, K., Pertea, M., Rongvaux, A., Wang, L., Durand, C. M., Ghiaur, G., Lai, J., McHugh, H. L., Hao, H., Zhang, H., et al. (2015) · Nature · doi:10.1038/nature14053 · Cited by 504
Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2014) · Nature Medicine · doi:10.1038/nm.3489 · Cited by 488
Redefining the Viral Reservoirs that Prevent HIV-1 Eradication
Eisele, E., & Siliciano, R. F. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.010 · Cited by 474
Transcriptional and Posttranscriptional Regulation of HIV-1 Gene Expression
Karn, J., & Stoltzfus, C. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006916 · Cited by 437
HIV-1 persistence in CD4+ T cells with stem cell–like properties
Buzon, M. J., Sun, H., Li, C., Shaw, A., Seiss, K., Ouyang, Z., Martin-Gayo, E., Leng, J., Henrich, T. J., Li, J. Z., et al. (2014) · Nature Medicine · doi:10.1038/nm.3445 · Cited by 414
Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
Laird, G. M., Bullen, C. K., Rosenbloom, D. I. S., Martin, A. R., Hill, A. L., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80142 · Cited by 391
Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells
Bosque, A., & Planelles, V. (2009) · Blood · doi:10.1182/blood-2008-07-168393 · Cited by 340
Maldarelli, F., Wu, X., Su, L., Simonetti, F., Wells, D., Shao, W., Spindler, J., Ferris, A., Mellors, J., Kearney, M., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000479721.09749.2d · Cited by 294
Wei, D. G., Chiang, V., Fyne, E., Balakrishnan, M., Barnes, T., Graupe, M., Hesselgesser, J., Irrinki, A., Murry, J. P., Stepan, G., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004071 · Cited by 273
Ylisastigui, L., Archin, N. M., Lehrman, G., Bosch, R. J., & Margolis, D. M. (2004) · AIDS · doi:10.1097/00002030-200405210-00003 · Cited by 254
Siliciano, J. D., & Siliciano, R. F. (2005) · Human Retrovirus Protocols · doi:10.1385/1-59259-907-9:003 · Cited by 242
Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay
Laird, G. M., Eisele, E. E., Rabi, S. A., Lai, J., Chioma, S., Blankson, J. N., Siliciano, J. D., & Siliciano, R. F. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003398 · Cited by 239
HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
Archin, N. M., Bateson, R., Tripathy, M. K., Crooks, A. M., Yang, K.-H., Dahl, N. P., Kearney, M. F., Anderson, E. M., Coffin, J. M., Strain, M. C., et al. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu155 · Cited by 237
Prins, J. M., Jurriaans, S., van Praag, R. M. E., Blaak, H., van Rij, R., Schellekens, P. T. A., ten Berge, I. J. M., Yong, S.-L., Fox, C. H., Roos, M. T. L., et al. (1999) · AIDS · doi:10.1097/00002030-199912030-00012 · Cited by 237
Jones, R. B., O'Connor, R., Mueller, S., Foley, M., Szeto, G. L., Karel, D., Lichterfeld, M., Kovacs, C., Ostrowski, M. A., Trocha, A., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004287 · Cited by 206
Rasmussen, T. A., Søgaard, O. S., Brinkmann, C., Wightman, F., Lewin, S. R., Melchjorsen, J., Dinarello, C., Østergaard, L., & Tolstrup, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23800 · Cited by 193
Self-citationPasternak, A. O., Adema, K. W., Bakker, M. E., Jurriaans, S., Berkhout, B., Cornelissen, M. T. E., & Lukashov, V. V. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00055-08 · Cited by 148
Cell-associated HIV RNA: a dynamic biomarker of viral persistence
Pasternak, A. O., Lukashov, V. V., & Berkhout, B. (2013) · Retrovirology · doi:10.1186/1742-4690-10-41 · Cited by 139
Wightman, F., Ellenberg, P. C., Churchill, M. J., & Lewin, S. R. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.95 · Cited by 133
Pollard, R. B., Rockstroh, J. K., Pantaleo, G., Asmuth, D. M., Peters, B. S., Lazzarin, A., García, F., Ellefsen, K., Podzamczer, D., van Lunzen, J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70343-8 · Cited by 109
Self-citationDynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell Model
Mohammadi, P., di Iulio, J., Muñoz, M., Martínez, R., Bartha, I., Cavassini, M. L., Thorball, C. W., Fellay, J., Beerenwinkel, N., Ciuffi, A., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004156 · Cited by 89
Koelsch, K. K., Boesecke, C., McBride, K. L., Gelgor, L., Fahey, P. P., Natarajan, V., Baker, D., Bloch, M. T., Murray, J. M., Zaunders, J., et al. (2011) · AIDS · doi:10.1097/qad.0b013e32834b9658 · Cited by 81
Self-citationComparative analysis of triplex nucleic acid test assays in United States blood donors
Stramer, S. L., Krysztof, D. E., Brodsky, J. P., Fickett, T. A., Reynolds, B., Dodd, R. Y., & Kleinman, S. H. (2013) · Transfusion · doi:10.1111/trf.12178 · Cited by 62
Romidepsin for the treatment of T-cell lymphomas
McGraw, A. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120163 · Cited by 35
Schmudde, M., Friebe, E., Sonnemann, J., Beck, J. F., & Bröker, B. M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.024 · Cited by 22
Methods for the analysis of histone H3 and H4 acetylation in blood
Rigby, L., Muscat, A. M., Ashley, D. M., & Algar, E. M. (2012) · Epigenetics · doi:10.4161/epi.20983 · Cited by 22
Roboz, G. J., Jabbour, E. J., Faderl, S. H., & Douer, D. (2014) · PubMed · Cited by 12
Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer
Laille, E. J., Patel, M. R., Jones, S. F., Burris, H. A., Infante, J. R., Lemech, C., Liu, L., & Arkenau, H. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.560 · Cited by 10
Cited by
International AIDS Society global scientific strategy: towards an HIV cure 2016
International AIDS Society Towards a Cure Working Group, Deeks, S. G., Lewin, S. R., Ross, A. L., Ananworanich, J., Benkirane, M., Cannon, P., Chomont, N., Douek, D., Lifson, J. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4108 · Cited by 425
Self-citationRecent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV
Kim, Y., Anderson, J. L., & Lewin, S. R. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.004 · Cited by 414
Pollack, R. A., Jones, R. B., Pertea, M., Bruner, K. M., Martin, A. R., Thomas, A. S., Capoferri, A. A., Beg, S. A., Huang, S.-H., Karandish, S., et al. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.03.008 · Cited by 370
Targeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
Metadata
- Authors
- Søgaard, O. S., Graversen, M. E., Leth, S., Olesen, R., Brinkmann, C. R., Nissen, S. K., Kjaer, A. S., Schleimann, M. H., Denton, P. W., Hey-Cunningham, W. J., Koelsch, K. K., Pantaleo, G., Krogsgaard, K., Sommerfelt, M., Fromentin, R., Chomont, N., Rasmussen, T. A., Østergaard, L., & Tolstrup, M.
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-09-17
- Volume
- 11
- Issue
- 9
- Pages
- e1005142
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2098194107
- Cited by
- 516
- References
- 50
- FWCI
- 29.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.